CAR T-Cells Multiple Myeloma: Adam Sperling, MD, PhD
Adam Sperling, MD, PhD provides an update on BCMA CAR T cells and shares a preview of next steps in CAR T development for multiple myeloma. Presented at the 2022 Dana-Farber Cancer Institute Multiple Myeloma Patient Education Symposium. For more information, visit: https://www.dana-farber.org/multiple-...
▶︎
CAR T Cells in Multiple Myeloma
▶︎
Updated Version Available - All About CARVYKTI #myeloma
▶︎
In Vivo CAR T-Cell Therapeutics With Umoja Biopharma's Dr. Andrew Scharenberg
▶︎
Metabolism, Mitochondria & Bipolar Disorder - Chris Palmer MD
▶︎
'CANCER OCCURRED near injection sites...': Bombshell testimony ‘EXPOSES’ COVID-19 vaccine injuries
▶︎
Learn Your Labs | High Impact Topic (HIT)
▶︎
Myeloma 101: Understanding Multiple Myeloma, Risk Factors, Diagnosis & Treatments Explained
▶︎
CAR T-Cell Therapy | Everything You Need to Know | Discussion with Dr. Prasad Narayanan
▶︎
CAR T-cells in Multiple Myeloma
▶︎
Lymphoma: Overview of Chimeric Antigen Receptor (CAR) T cells
▶︎
Recent Advances in Multiple Myeloma with Dr. Dan Vogl
▶︎
Anito-Cel, a novel anti-BCMA CAR T-cell, for Relapsed/Refractory Myeloma | Ciara Freeman | #ASH24
▶︎
Prostate Cancer Cure Explained: PSA, Recurrence, and Survival
▶︎
Challenges with the real-world use of CAR-T therapy in multiple myeloma
▶︎
Multiple Myeloma - Malignancy of Plasma Cells - Bone marrow - Hematology & Oncology
▶︎
Understanding CAR T-cell therapy (November 2020)
▶︎
CAR T and Bispecific Antibody Therapies in Multiple Myeloma
▶︎
CAR-T Cells: Engineered Cancer Killers, Mechanism of Action
▶︎
Multiple Myeloma - signs and symptoms, pathophysiology, treatment
▶︎